Figures computed from official regulatory filings — .
Analysttarget 0.67 USD (+408%) · consensus 4/5 · 1 buy · 0 hold · 0 sell
Ownershipinsiders 7.59% · institutions 32.04% · short 1.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Azitra, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
16 buys6 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Salva Francisco D. | Other | n/a (No price was disclosed in the filing) | SEC |
| Salva Francisco D. | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Salva Francisco D. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Staskey Norm | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Whitfill Travis | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Salva Francisco D. | BuyD (derivative) | n/a (No price was disclosed in the filing) | First in 12mo | SEC |
| Salva Francisco D. | BuyD (derivative) | n/a (No price was disclosed in the filing) | First in 12mo | SEC |
| Salva Francisco D. | BuyD (derivative) | n/a (No price was disclosed in the filing) | First in 12mo | SEC |
| Salva Francisco D. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Whitfill Travis | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ryan Barbara | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Schroer John R. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Staskey Norm | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Staskey Norm | Buy | $10K | conv 89Cluster | SEC |
| Salva Francisco D. | Buy | $100K | conv 98ClusterFirst in 12mo | SEC |
| Staskey Norm | Buy | $990 | conv 99ClusterFirst in 12mo | SEC |
| Whitfill Travis | Buy | $4.5K | conv 70ClusterFirst in 12mo | SEC |
| Whitfill Travis | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Schroer John R. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ryan Barbara | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Staskey Norm | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bayer World Investments B.V. | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bayer World Investments B.V. | Other | n/a (No price was disclosed in the filing) | SEC |
| McClary Andrew | Other | n/a (No price was disclosed in the filing) | SEC |
| McClary Andrew | Other | n/a (No price was disclosed in the filing) | SEC |